HC Wainwright & Co. initiated coverage of Autolus Therapeutics with a 'Buy' rating and a $10 price target. This represents a substantial potential upside from the recent closing price, likely generating positive investor sentiment and increased trading activity for Autolus.
HC Wainwright & Co. has assumed coverage of Autolus Therapeutics, assigning a 'Buy' rating and a $10.00 price target. This is a significant positive development for Autolus as it signals increased institutional interest and a strong vote of confidence from a reputable investment bank. The price target of $10.00 represents a substantial upside from the recent closing price of $1.52, which could attract new investors and drive short-term price appreciation. For traders, this presents a clear opportunity for a bullish play on AUTL, though the long-term success will still depend on the company's clinical pipeline and commercial execution. The key risk is that the price target may not be realized if the company fails to meet expectations or if broader market conditions deteriorate.